Cytomegalovirus retinitis and viral resistance: Prevalence of resistance at diagnosis, 1994

Archives of Ophthalmology

Volumn 114, Issue 7, 1996, Pages 809-814

  Jabs, Douglas A ^a,b   Dunn, J P ^a   Enger, Cheryl ^a   Forman, Michael ^a   Bressler, Neil ^a   Charache, Patricia ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FOSCARNET; GANCICLOVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; BLOOD CULTURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS; DIAGNOSTIC ACCURACY; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG RESISTANCE; EPIDEMIOLOGICAL DATA; HUMAN; MAINTENANCE THERAPY; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETINITIS; URINE CULTURE; VIRUS ISOLATION; VIRUS RESISTANCE;

EID: 0029895692     PISSN: 00039950     EISSN: None     Source Type: Journal    
DOI: 10.1001/archopht.1996.01100140023002     Document Type: Article

References (33)

1. Holland GN, Pepose JS, Pettit TH, Gottlieb MS, Yee RD, Foos RY. Acquired immune deficiency syndrome: ocular manifestations. Ophthalmology. 1983; 90:859-873.
2. Palestine AG, Rodrigues MM, Macher AM, et al. Ophthalmic involvement in acquired immunodeficiency syndrome. Ophthalmology. 1984;91:1092-1099.
3. Freeman WR, Lerner CW, Mines JA, et al. A prospective study of the ophthalmologic findings in the acquired immune deficiency syndrome. Am J Ophthalmol. 1984;97:133-142.
4. Pepose JS, Holland GN, Nestor MS, Cochran AJ, Foos RY. Acquired immune deficiency syndrome: pathogenic mechanisms of ocular disease. Ophthalmology. 1985;92:472-484.
5. Jacobson MA, Mills J. Serious cytomegalovirus disease in the acquired immunodeficiency syndrome (AIDS). Ann Intern Med. 1988;108:585-594.
6. Jabs DA, Enger C, Bartlett JG. Cytomegalovirus retinitis and acquired immunodeficiency syndrome. Arch Ophthalmol. 1989;107:75-80.
7. Pertel P, Hirschtick R, Phair J, Chmiel J, Poggensee L, Murphy R. Risk of developing cytomegalovirus retinitis in persons infected with the human immunodeficiency virus. J Acquir Immune Defic Syndr Hum Retrovirol. 1992;5: 1069-1074.
8. Gallant JE, Moore RD, Richman DD, Keruly J, Chaisson RE, for the Zidovudine Epidemiology Study Group. Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine. J Infect Dis. 1992;166:1223-1227.
9. Hoover DR, Saah AJ, Bacellar H, et al. Clinical manifestations of AIDS in the era of Pneumocystis prophylaxis. N Engl J Med. 1993;329:1922-1926.
10. Collaborative DHPG Treatment Study Group. Treatment of serious cytomegalovirus infections with 9-(1,3-dihydroxy-2-propoxymethyl)guanine in patients with AIDS and other immunodeficiencies. N Engl J Med. 1986;314:801-805.
11. Holland GN, Buhles WC Jr, Mastre B, Kaplan HJ, and the UCLA CMV Retinopathy Study Group. A controlled retrospective study of ganciclovir treatment for cytomegalovirus retinopathy: use of a standardized system for the assessment of disease outcome. Arch Ophthalmol. 1989;107:1759-1766.
12. Gross JG, Bozzette SA, Mathews WC, et al. Longitudinal study of cytomegalovirus retinitis in acquired immune deficiency syndrome. Ophthalmology. 1990; 97:681-686.
13. Spector SA, Weingeist T, Pollard RB, et al. A randomized, controlled study of intravenous ganciclovir therapy for cytomegalovirus peripheral retinitis in patients with AIDS. J Infect Dis. 1993;168:557-563.
14. Palestine AG, Polis MA, De Smet MD, et al. A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS. Ann Intern Med. 1991;115:665-673.
15. Studies of Ocular Complications of AIDS Research Group in Collaboration With the AIDS Clinical Trials Group. Foscarnet-ganciclovir cytomegalovirus retinitis trial, 4: visual outcomes. Ophthalmology 1994;101:1250-1261.
16. The Oral GCV European and Australian Cooperative Study Group. Intravenous versus oral ganciclovir: European/Australian comparative study of efficacy and safety in the prevention of cytomegalovirus retinitis recurrence in patients with AIDS. AIDS. 1995;9:471-477.
17. Drew WL, Ives D, Lalezari JP, et al. Oral ganciclovir as maintenance treatment for cytomegalvirus retinitis in patients with AIDS. N Engl J Med. 1995;333: 615-620.
18. Martin DF, Parks DJ, Mellow SD, et al. Treatment of cytomegalovirus retinitis with an intraocular sustained-release ganciclovir implant: a randomized controlled clinical trial. Arch Ophthalmol. 1994;112:1531-1539.
19. Drew WL, Miner RC, Busch DF, et al. Prevalence of resistance in patients receiving ganciclovir for serious cytomegalovirus infection. J Infect Dis. 1991; 163:716-719.
20. Erice A, Chou S, Biron KK, Stanat SC, Balfour HH Jr, Jordan MC. Progressive disease due to ganciclovir-resistant cytomegalovirus in immunocompromised patients. N Engl J Med. 1989;320:289-293.
21. Knox KK, Drobyski WR, Carrigan DR. Cytomegalovirus isolate resistant to ganciclovir and foscarnet from a marrow transplant patient. Lancet. 1991;337: 1292-1293.
22. Sullivan V, Coen DM. Isolation of foscarnet-resistant human cytomegalovirus patterns of resistance and sensitivity to other antiviral drugs. J Infect Dis. 1991; 164:781-784.
23. Flores-Aguilar M, Kuppermann BD, Quiceno JI, et al. Pathophysiology and treatment of clinically resistant cytomegalovirus retinitis. Ophthalmology. 1993; 100:1022-1031.
24. Dunn JP, MacCumber MW, Forman MS, Charache P, Apuzzo L, Jabs DA. Viral sensitivity testing in patients with cytomegalovirus retinitis clinically resistant to foscarnet or ganciclovir. Am J Ophthalmol. 1995;119:587-596.
25. Danker WM, Scholl D, Stanat SC, Martin M, Sonke RL, Spector SA. Rapid antiviral DNA-DNA hybridization assay for human cytomegalovirus. J Virol Methods. 1990;28:293-298.
26. Drew WL, Miner RC, Saleh E. Antiviral susceptibility of cytomegalovirus: criteria for detecting resistance to antivirals. Clin Diagn Virol. 1993;1:179-185.
27. Swierkosz E, Biron K. Antiviral susceptibility testing. In: Isenberg HD, ed. Clinical Microbiology Procedure Handbook Supplement II. Washington, DC: American Society for Microbiology; 1994;2:8.26.1-8.26.21.
28. Jabs DA. Ocular manifestations of HIV infection. Trans Am Ophthalmol Soc. 1995;93:623-683.
29. Jacobson MA, Drew WL, Feinberg J, et al. Foscarnet therapy for ganciclovir-resistant cytomegalovirus retinitis in patients with AIDS. J Infect Dis. 1991; 163:1348-1351.
30. Aweeka F, Ganbertoglio J, Mills J, Jacobson MA. Pharmacokinetics of intermittently administered intravenous foscarnet in the treatment of acquired immunodeficiency syndrome patients, with serious cytomegalovirus retinitis. Antimicrob Agents Chemother. 1989;33:742-745.
31. Kupperman BD, Quiceno JI, Flores-Aguilar M, et al. Intravitreal ganciclovir concentration after intravenous administration in AIDS patients with cytomegalovirus retinitis: implications for therapy. J Infect Dis. 1993;168:1506-1509.
32. Drew WL, Sweet ES, Miner RC, Mocarski ES. Multiple infections by cytomegalovirus in patients with acquired immunodeficiency syndrome: documentation by Southern blot hybridization. J Infect Dis. 1984;150:952-953.
33. Spector SA, Hirata KK, Neuman TR. Identification of multiple cytomegalovirus strains in homosexual men with acquired immunodeficiency syndrome. J Infect Dis. 1984;150:953-956.